Dean Hart
Chief Executive Officer at RS Biotherapeutics, Inc.
Profile
Dean Hart is currently the Chief Executive Officer at RS Biotherapeutics, Inc. He previously worked as the Director of National Sales at Eisai, Inc., Principal at Bristol Myers Squibb Co., Senior Vice President of Sales at Adamas Pharmaceuticals LLC, Vice President of Sales & Marketing at Vision Point of Sale, Inc., President at Sequest Technologies, Inc., Senior Vice President of Sales at Takeda Pharmaceuticals U.S.A., Inc., Vice President of Marketing & Communications at Coast Central Credit Union, and Senior Vice President at Delta Point Associates Ltd.
He also served as the Chief Commercial Officer at NanoInk, Inc. from 2011 to 2013.
Mr. Hart holds a Master's in Business Administration from Northwestern University and an undergraduate degree from Indiana University.
Dean Hart active positions
| Companies | Position | Start |
|---|---|---|
RS Biotherapeutics, Inc.
 RS Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology RS Biotherapeutics, Inc. is a company focused on developing life-changing medicines for people suffering from diseases characterized by pulmonary inflammation. RS Biotherapeutics is based in Cumberland, MD. The company's mission is to develop a first-in-class agent, rsbt-001, for the treatment of respiratory diseases such as idiopathic pulmonary fibrosis (IPF) and chronic obstructive lung disease (COPD). The company owns the exclusive license for rsbt-001 and is projecting to file an investigational new drug application for rsbt-001 in 2025. Dean Hart has been the CEO of the company since 2023. | Chief Executive Officer | 10/04/2023 |
Former positions of Dean Hart
| Companies | Position | End |
|---|---|---|
| ADAMAS PHARMACEUTICALS, INC. | Sales & Marketing | 01/08/2019 |
NanoInk, Inc.
 NanoInk, Inc. Industrial MachineryProducer Manufacturing NanoInk, Inc. is an emerging growth technology company specializing in nanometer-scale manufacturing and applications development for the life sciences, engineering, pharmaceutical, and education industries. Using Dip Pen Nanolithography® (DPN®), a patented and proprietary nanofabrication technology, scientists are enabled to rapidly and easily create micro-and nanoscale structures from a variety of materials on a range of substrates. This low cost, easy to use and scalable technique brings sophisticated nanofabrication to the laboratory desktop. Headquartered in the Illinois Science + Technology Park, north of Chicago, NanoInk currently has over 250 patents and applications filed worldwide and licensing agreements with Northwestern University, Stanford University, University of Strathclyde, University of Liverpool, California Institute of Technology and the University of Illinois at Urbana-Champaign. | Corporate Officer/Principal | 26/08/2013 |
Delta Point Associates Ltd.
 Delta Point Associates Ltd. Packaged SoftwareTechnology Services Delta Point Associates Ltd. used to provide automotive intelligence services and vehicle valuation software applications. The company was headquartered in Chester, the United Kingdom. | Corporate Officer/Principal | - |
Coast Central Credit Union
 Coast Central Credit Union Savings BanksFinance Coast Central Credit Union is a non-profit organization which operates as a state chartered credit union. It offers services for personal and business platforms. For Presonal platform It provides financial advising, online banking, mobile banking, and direct deposit services. For business platform, it offers merchant card processing, online banking, and mibile banking services. The company was founded in 1979 and is headquartered in Eureka, CA. | Investor Relations Contact | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Training of Dean Hart
| Northwestern University | Masters Business Admin |
| Indiana University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Private companies | 9 |
|---|---|
NanoInk, Inc.
NanoInk, Inc. Industrial MachineryProducer Manufacturing NanoInk, Inc. is an emerging growth technology company specializing in nanometer-scale manufacturing and applications development for the life sciences, engineering, pharmaceutical, and education industries. Using Dip Pen Nanolithography® (DPN®), a patented and proprietary nanofabrication technology, scientists are enabled to rapidly and easily create micro-and nanoscale structures from a variety of materials on a range of substrates. This low cost, easy to use and scalable technique brings sophisticated nanofabrication to the laboratory desktop. Headquartered in the Illinois Science + Technology Park, north of Chicago, NanoInk currently has over 250 patents and applications filed worldwide and licensing agreements with Northwestern University, Stanford University, University of Strathclyde, University of Liverpool, California Institute of Technology and the University of Illinois at Urbana-Champaign. | Producer Manufacturing |
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
Eisai, Inc.
 Eisai, Inc. Pharmaceuticals: MajorHealth Technology Eisai, Inc. manufactures pharmaceuticals products. It focuses on neurology, gastrointestinal disorders and oncology critical care. The company was founded in 1995 and is headquartered in Woodcliff Lake, NJ. | Health Technology |
Vision Point of Sale, Inc.
 Vision Point of Sale, Inc. Electronics DistributorsDistribution Services Vision Point of Sale, Inc. provides refurbished computer related hardware. The company was founded by Frank D. Muscarello on April 17, 1995 and is headquartered in Glenview, IL. | Distribution Services |
| Sequest Technologies, Inc. | Technology Services |
Takeda Pharmaceuticals U.S.A., Inc.
 Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Health Technology |
Coast Central Credit Union
Coast Central Credit Union Savings BanksFinance Coast Central Credit Union is a non-profit organization which operates as a state chartered credit union. It offers services for personal and business platforms. For Presonal platform It provides financial advising, online banking, mobile banking, and direct deposit services. For business platform, it offers merchant card processing, online banking, and mibile banking services. The company was founded in 1979 and is headquartered in Eureka, CA. | Finance |
Delta Point Associates Ltd.
Delta Point Associates Ltd. Packaged SoftwareTechnology Services Delta Point Associates Ltd. used to provide automotive intelligence services and vehicle valuation software applications. The company was headquartered in Chester, the United Kingdom. | Technology Services |
RS Biotherapeutics, Inc.
RS Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology RS Biotherapeutics, Inc. is a company focused on developing life-changing medicines for people suffering from diseases characterized by pulmonary inflammation. RS Biotherapeutics is based in Cumberland, MD. The company's mission is to develop a first-in-class agent, rsbt-001, for the treatment of respiratory diseases such as idiopathic pulmonary fibrosis (IPF) and chronic obstructive lung disease (COPD). The company owns the exclusive license for rsbt-001 and is projecting to file an investigational new drug application for rsbt-001 in 2025. Dean Hart has been the CEO of the company since 2023. | Health Technology |
- Stock Market
- Insiders
- Dean Hart
